about
Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopiAnti-thrombotic therapy of acute coronary syndromes without ST elevationEnoxaparin in unstable angina patients who would have been excluded from randomized pivotal trialsMedical treatment of acute coronary syndrome without ST-segment elevationImmediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial.Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis.Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.Primary percutaneous coronary intervention for ST elevation myocardial infarction in nonagenarians.Impact of renal failure on all-cause mortality and other outcomes in patients treated by percutaneous coronary intervention.Correlation between Chlamydia pneumoniae detection from coronary angioplasty balloons and atherosclerosis severity.A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention.Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).Long-term follow-up of patients with sirolimus-eluting stents for treatment of bare-metal in-stent restenosis.Feasibility of outpatient coronary angiography with "ad hoc" angioplasty.Low molecular weight heparin use in percutaneous coronary intervention.Periprocedural myocardial infarction and injury in elective coronary stenting.Prognosis of moderate coronary artery lesions in heart transplant patients.Sex-related differences after contemporary primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.Heparin or enoxaparin anticoagulation for primary percutaneous coronary interventionTriple vessel stenting for triple vessel coronary diseaseImages in cardiovascular medicine. Recurrent myocardial infarction in a patient with paroxysmal nocturnal hemoglobinuria
P50
Q28166874-4FE0080D-0AC9-4A37-94E8-8FFC856858C6Q28188639-3C0BCEFF-D014-43FE-A165-9AAFA2C32B0FQ28194868-1AAF25FF-07FA-4F67-AE83-9E6B74CA04A5Q28196068-F1A0895D-7B2F-48CE-8BEA-3CAD1E90043FQ35000773-EB825007-F42F-4271-8FA1-03EED805CE25Q35826954-91E3EE1E-82F6-495C-9240-D0CBA1118077Q36131116-3C6ACE1C-26B2-4FD7-97A2-05472F294C45Q37398937-AE29EEE2-243B-4E07-A607-EFCE691EFFC1Q41577137-C2353D36-4DA2-421E-A52E-E613026F1397Q43418432-9BE99770-8FA4-4C2C-B7E2-C5F127F5BD5FQ44244531-BF73CBCB-1229-4408-A86C-74335B6681BFQ44397609-7B54E91D-020E-42F0-A724-ACB5A7633052Q46218840-7DD2A869-032A-4C8B-80CC-CC845DA6515FQ46353090-2FF01430-3E72-4757-9D5C-4A34BC1C126BQ47242145-1E3BD81F-5669-42D6-848F-B21B07628289Q49819606-12083DAC-82AD-4819-ACE2-ACF66C99167EQ50714376-590FA527-C65C-45F4-B32A-31F4AE8F031CQ51027956-D8F7D12F-D143-4DF2-8A6B-2EAF96D89DB0Q56837771-8B8D7FC7-7911-4CB1-8635-3FFC1160D595Q77439580-1905E138-88B1-4E76-8333-BB51866D9ECDQ79096652-4157C1CA-2276-49E1-93B6-97E3528F5B8C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Rémi Choussat
@ast
Rémi Choussat
@en
Rémi Choussat
@es
Rémi Choussat
@nl
Rémi Choussat
@sl
type
label
Rémi Choussat
@ast
Rémi Choussat
@en
Rémi Choussat
@es
Rémi Choussat
@nl
Rémi Choussat
@sl
prefLabel
Rémi Choussat
@ast
Rémi Choussat
@en
Rémi Choussat
@es
Rémi Choussat
@nl
Rémi Choussat
@sl